The Leukemia & Lymphoma Society (LLS) has issued new requests for proposals from researchers in six critical areas of unmet medical need. The RFPs mark LLS’s aggressive and proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. LLS aims to stimulate more academic research in these areas. New immunotherapeutics for patients with acute myelogenous leukemia;
- Novel therapeutics for patients with non-cutaneous T-cell malignancies;
- Introduction of novel agents in the treatment of patients with diffuse large B-cell lymphoma and mantle cell lymphoma;
- Therapies for patients with myelodysplastic syndromes (MDS) who have failed hypomethylating agents;
- Therapies for new targets such as bromodomains, methylation and other epigenetic approaches for patients with high-risk myeloma;
- Research that addresses long-term and late effects of blood cancer therapies.
Upon reviewing responses to these requests, LLS will award grants under its Translational Research Program, an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant will be for a three-year duration with a total value of up to $600,000.